NEW YORK (Reuters Health)—Growth hormone is associated with a decrease in fractures in women with postmenopausal osteoporosis even a decade after treatment ceases, researchers from Sweden report. “We were surprised and pleased to find that the patients had a reduced risk of fracture so many years after the growth hormone treatment was ceased,” Dr. Emily…
Search results for: fracture
Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website
In a 25 month Phase 3 trial, abaloparatide-SC reduced the risk of new fractures in patients suffering from postmenopausal osteoporosis. Plus, the FDA launches a new drug safety website.
2014 ACR/ARHP Annual Meeting: Bone Fracture Concerns in Children
Recognizing, reducing risk of bone fractures in pediatric patients with rheumatic disease, taking glucocorticoid therapy
Atypical Fractures Associated with Bisphosphonates
Plus, FX006, odanacatib and other rheumatology drug news, safety updates
New Treatments Needed to Prevent Fractures in Osteoporosis
Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact
Unexpected Benefits of Bisphosphonates after Hip Fracture
Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.
Glucocorticoids a Fracture Risk at Any Dose
Updated recommendations advocate doing more to determine fracture risk and the need for preventive therapy
Concrete Relief for Vertebral Fractures
PVA reduces fracture pain—but is it overused?
FDA Issues Boxed Warning for Denosumab & Approves a Generic NSAID
In January, the U.S. Food & Drug Administration approved indomethacin in an oral suspension, a generic version of Indocin Oral Suspension. The agency also issued a boxed warning and updated label for denosumab, warning of the risks of severe hypocalcemia in patients with chronic kidney disease.
To the Bone: Experts Discuss Developments in Osteoporosis Care
During ACR Convergence 2023, experts discussed developments in the treatment and diagnosis of osteoporosis, addressing risks of treatment discontinuation, the use of bone turnover markers in patient assessment and vitamin D.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 42
- Next Page »